Draper-based Xenter has raised $58.25 million in Series B funding, an amount that appears to be the largest disclosed funding round in 2026 by a Utah-headquartered Life Sciences company, according to a report published August 18.
The company intends to use the capital to commercially launch Xenter Diagnostics and continue work on its investigational medical devices and AI-empowered healthcare technologies.
The Series B funding came from existing shareholders, healthcare investors, and prominent family offices, though Xenter did not disclose the specific names of these investors or the company's current valuation.
One primary use for the funds is the commercial launch of Xenter Diagnostics. This business line offers a cognitive-assessment program that combines brain-activity testing with a blood biomarker panel related to Alzheimer’s disease pathology. The offering utilizes a U.S. Food and Drug Administration-cleared cognitive-assessment device and produces reports reviewed by neurologists.
Beyond diagnostics, Xenter is developing investigational medical devices designed to capture physiological information during therapeutic and diagnostic procedures. These devices are intended to transmit data wirelessly into AI applications and healthcare data via the XenFi wireless medical ecosystem. One such product in development is Guru, a dual-sensor physiology guidewire for transcatheter aortic valve replacement procedures.
The $58.25 million in proceeds will support manufacturing expansion, clinical and regulatory initiatives, and the continued development of proprietary technologies.
While Xenter has raised just shy of $80 million in publicly disclosed fundings since its formal launch in 2020, the company has not disclosed the specific allocation of the new capital or how long the funding is expected to finance operations.
